72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon α-2a plus adefovir vs. peginterferon α-2a plus placebo vs. adefovir in chronic delta hepatitis

Wedemeyer, H.Yurdaydin, C.Dalekos, G.Erhardt, A.Cakaloglu, Y.Degertekin, H.Gürel, S.Zeuzem, S.Bock, T.Zachou, K.Bozkaya, H.Drebber, U.Meyer, S.Dienes, H. P.Manns, M. P.2024-11-202024-11-202007-01-010168-8278https://www.sciencedirect.com/science/article/pii/S016882780761602Xhttps://hdl.handle.net/11452/48193Bu çalışma, 11-15, Nisan 2007 tarihlerinde Barcelona[İspanya]’da düzenlenen 42. Annual Meeting of the European-Association-for-the-Study-of-the-Liver Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatology72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon α-2a plus adefovir vs. peginterferon α-2a plus placebo vs. adefovir in chronic delta hepatitisMeeting Abstract000246555100005S4S446Supplement 110.1016/S0168-8278(07)61602-X